Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 3374
  • Home
  • Print this page
  • Email this page

   Table of Contents      
LETTER TO EDITOR
Year : 2007  |  Volume : 55  |  Issue : 4  |  Page : 319

Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity


Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, Ansari Nagar, New Delhi - 110 029, India

Correspondence Address:
Rajvardhan Azad
Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, Ansari Nagar, New Delhi - 110 029
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0301-4738.33057

Rights and Permissions

How to cite this article:
Azad R, Chandra P. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 2007;55:319

How to cite this URL:
Azad R, Chandra P. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol [serial online] 2007 [cited 2020 Aug 12];55:319. Available from: http://www.ijo.in/text.asp?2007/55/4/319/33057

Dear Editor,

We read with interest the article by Shah et al . [1] regarding the use of intravitreal bevacizumab (Avastin) for post-laser anterior segment ischemia in aggressive posterior (AP) retinopathy of prematurity (ROP). We have a few concerns which we mention below.

Bevacizumab is an off-label drug, with ethical issues associated with its usage and though the authors tried it for the first time in a premature baby with ROP, there is no mention if ethical clearance was obtained.

Besides the mention of AP-ROP, the authors have not described the zone, stage, clock hours or plus disease of the case or if there was a difference in presentation in either eye. There is no description or preoperative photographs to document the status of tunica vasculosa lentis (commonly seen in premature babies) which can be confused with the iris neovascularization. Its vascularity may have fluctuated with severity of plus disease and regressed automatically over a period of time. The ocular hypotony may occur due to repeated scleral indentation and choroidal effusion following extensive laser treatment in AP-ROP.

It would be interesting to know if they tried oral or intravenous steroids to decrease the severe ocular inflammation, before suggesting bevacizumab. Based on the author's view that thermal injury to the long posterior ciliary arteries could have caused this problem, what modifications to laser treatment do they suggest to avoid such complications?

Vitreous haze and ocular inflammation can occur following extensive confluent laser treatment, especially due to the large area that needs to be photocoagulated in AP-ROP. We cannot be sure if severe anterior segment ischemia was present and enough to warrant use of an off-label drug like bevacizumab in a premature child.

 
  References Top

1.
Shah PK, Narendran V, Tawansy KA, Raghuram A, Narendran K. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 2007;55:75-6.  Back to cited text no. 1
    



This article has been cited by
1 Off-label use of intravitreal bevacizumab for severe retinopathy of prematurity
L.E. Alba,R.A. Zaldua,R.A. Masini
Archivos de la Sociedad Española de Oftalmología (English Edition). 2015;
[Pubmed] | [DOI]
2 Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease
Marcel N Menke,Carsten Framme,Mathias Nelle,Markus R Berger,Veit Sturm,Sebastian Wolf
BMC Ophthalmology. 2015; 15(1)
[Pubmed] | [DOI]
3 Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity
S. G. Tahija,R. Hersetyati,G. C. Lam,S. Kusaka,P. G. McMenamin
British Journal of Ophthalmology. 2014; 98(4): 507
[Pubmed] | [DOI]
4 Uso off-label de bevacizumab intravítreo en retinopatía del prematuro severa
L.E. Alba,R.A. Zaldua,R.A. Masini
Archivos de la Sociedad Española de Oftalmología. 2014;
[Pubmed] | [DOI]
5 An Updated Study of the Use of Bevacizumab in the Treatment of Patients with Prethreshold Retinopathy of Prematurity in Taiwan
Wei-Chi Wu,Hsi-Kung Kuo,Po-Ting Yeh,Chung-May Yang,Chi-Chun Lai,San-Ni Chen
American Journal of Ophthalmology. 2013; 155(1): 150
[Pubmed] | [DOI]
6 Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization
Frank Ong,Jane Kuo,Wei-Chi Wu,Ching-Yu Cheng,Wendell-Lamar Blackwell,Brian Taylor,Wayne Grody,Jerome Rotter,Chi-Chun Lai,Tien Wong
Journal of Personalized Medicine. 2013; 3(1): 40
[Pubmed] | [DOI]
7 Effects and Complications of Bevacizumab Use in Patients with Retinopathy of Prematurity: A Multicenter Study in Taiwan
Wei-Chi Wu,Po-Ting Yeh,San-Ni Chen,Chung-May Yang,Chi-Chun Lai,Hsi-Kung Kuo
Ophthalmology. 2011; 118(1): 176
[Pubmed] | [DOI]
8 Effects and complications of bevacizumab use in patients with retinopathy of prematurity: A multicenter study in Taiwan
Wu, W.-C., Yeh, P.-T., Chen, S.-N., Yang, C.-M., Lai, C.-C., Kuo, H.-K.
Ophthalmology. 2011; 118(1): 176-183
[Pubmed]
9 Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes
Wu, W.-C., Lai, C.-C., Chen, K.-J., Chen, T.-L., Wang, N.-K., Hwang, Y.-S., Yeung, L., Li, L.-M.
Investigative Ophthalmology and Visual Science. 2010; 51(7): 3701-3708
[Pubmed]
10 Bevacizumab (Avastin) for the Treatment of Ocular Disease
Jonathan B. Gunther,Michael M. Altaweel
Survey of Ophthalmology. 2009; 54(3): 372
[Pubmed] | [DOI]
11 Bevacizumab (Avastin) for the Treatment of Ocular Disease
Gunther, J.B., Altaweel, M.M.
Survey of Ophthalmology. 2009; 54(3): 372-400
[Pubmed]
12 Antibodies for therapeutic uses and the evolution of biotechniques
Nieri, P., Donadio, E., Rossi, S., Adinolfi, B., Podestà, A.
Current Medicinal Chemistry. 2009; 16(6): 753-779
[Pubmed]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed5073    
    Printed90    
    Emailed1    
    PDF Downloaded686    
    Comments [Add]    
    Cited by others 12    

Recommend this journal